Biologics Legislation In The 111th Congress

Law360, New York (April 6, 2009, 12:00 AM EDT) -- Two bills have been introduced in the House that aim to create an FDA approval process for follow-on biologics similar to that established for generic drugs in the Hatch-Waxman Act of 1984.

The first bill, H.R. 1427, the “Promoting Innovation and Access to Life-Saving Medicine Act”, outlines an approval process that is highly favorable to follow-on biologic companies, whereas the second bill, H.R. 1548, the “Pathway for Biosimilars Act”, stakes out a position somewhat more favorable to the innovator biologics industry. A new law could take...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.